The FDA Found No Problems With NRx's Ketamine Drug. One Packaging Question Is Still Holding Up Approval

NRx Pharmaceuticals announced that the FDA completed its first-cycle review of the company's ANDA — an abbreviated new drug application, the pathway used for a drug that relies on prior safety and efficacy data rather than running its own full clinical program — for a preservative-free ketamine product. The review found no major deficiencies related to the drug product itself, its ingredients, proposed labeling, manufacturing controls, or any other drug-related review matter. No new clinical, safety, or efficacy data is required for the application to move to approval.

The one item still open has nothing to do with the drug: it's a manufacturer certification for the vial's luer lock component, a small connector piece used to attach a syringe or IV line securely. That specific component is already used in three other FDA-approved ANDA products, with 11.9 million units shipped over the prior 12 months without a single complaint, return, adverse event, or recall — a track record that makes the outstanding item look procedural rather than substantive, even though it's the thing standing between the application and approval right now.

NRx held a clarification meeting with senior FDA leadership on August 6, 2026 specifically to confirm what's needed to close out the packaging certification, and the FDA committed to reviewing the requested certification on the shortest possible review cycle following that meeting. The company said it remains optimistic the issue can be resolved in time to enable initial commercial sales of the product in 2026.